▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Korea’s biotech firm SCM Lifescience said on Sept. 11 it has attracted 2 billion won (US$1.78 million) from the Yozma Group, an Israeli venture capital firm. With the investment, the...
[THE INVESTOR] ToolGen shares fell sharply on Sept. 11, wiping out over 224 billion won (US$198 million) from the company’s market cap over two days after news reports alleged that it stole patents ...
[THE INVESTOR] Hana Pharm said on Sept. 6 it plans to go public on the country’s main bourse next month to raise funds for facility investment to further advance its overseas market presence. It...
[THE INVESTOR] Celltrion Healthcare , the sales and marketing unit of biosimilar developer Celltrion, on Sept. 5 called on the UK’s public health service provider National Health Service to conside...
[THE INVESTOR] Alpha Holdings said in a regulatory filing on Sept. 3 that is seeking to enter the immune-oncology market by investing in NASDAQ-listed US firm OncoSec Medical. “Alpha Holdings has e...
[THE INVESTOR] Analysts are expecting Korean biotechnology and pharmaceutical stocks to gain momentum from this month with an upcoming international academic conference where the firms will present ...
[THE INVESTOR] Shrugging off concerns over overvaluation and uncertainties regarding accounting regulations, South Korea‘s pharmaceutical and bio companies have shown signs of regaining their presen...
[THE INVESTOR] L&C Bio, a tissue engineering company, said on Aug. 31 it has gained preliminary approval for its initial public offering on Korea‘s secondary bourse KOSDAQ. The company plans to flo...
[THE INVESTOR] Celltrion Healthcare , the marketing unit of biosimilar developer Celltrion , posted a 47 percent dip in first-half operating profit, hit by increased competition and lower selling...
[THE INVESTOR] Medytox said on Aug. 29 that it has filed a biologics license application with the Taiwan Food and Drug Administration for the sale of its botulinum toxin Neuronox. The news sent its ...
[THE INVESTOR] Celltrion said on Aug. 29 it has wrapped up phase 3 clinical trials for a subcutaneous formulation of its anti-inflammatory therapy Remsima, and will seek marketing approval in Europ...
[THE INVESTOR] Bukwang Pharmaceutical has secured over 80 billion won (US$72.13 million) through its investments in biotechnology companies. The investment return is 10 times bigger than its opera...
[THE INVESTOR] Daewoong Pharmaceutical Chairman Yoon Jae-seung said on Aug. 27 he will step down from all positions in the company following news reports of his abusive behavior against employees. ...
[THE INVESTOR ] Shares of JW Pharmaceutical rose over 5 percent on Aug. 27 as the Korean drug maker has signed a license agreement with Denmark-based LEO Pharma for its atopic dermatitis therapy i...
[THE INVESTOR] Korean medical device companies are establishing their presence and rapidly increasing their footprint in China, a huge market that is rapidly facing an aging society with rising medi...
Tinder, not just a dating app in Korea
Sandbox Network aims to go public by 2021
Activist fund to be more involved in Hanjin’s management
Unison Capital inches closer to selling Gong Cha Korea
Money20/20 Asia to include Token Day
Hana Financial kicks off in-house venture projects
Kakao Pay, KT to take part in govt’s Zero Pay
Yanolja hires former Tesla Motors Korea chief
January 23, 2019
